We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




New Imaging Approach Could Help Predict Dangerous Gut Infection

By LabMedica International staff writers
Posted on 10 Mar 2026

Clostridioides difficile infections affect roughly half a million people in the United States each year and are a leading cause of infectious diarrhea in healthcare settings. More...

The bacterium can trigger severe intestinal inflammation, recurring illness, and life-threatening complications, particularly in older adults. Despite available treatments, controlling C. diff infections remains difficult because the bacterium can survive harsh conditions and frequently reappears after treatment. Researchers are now investigating the bacterium at multiple biological levels to uncover vulnerabilities that could lead to improved prevention and treatment strategies.

Scientists at Tufts University School of Medicine (Boston, MA, USA) are studying how C. diff behaves inside the body and how its spores reactivate to cause infection. C. diff infections typically occur after antibiotics disrupt the natural gut microbiome, allowing the bacterium to colonize the colon and release toxins that damage intestinal tissues. To better understand how the infection progresses, researchers developed an imaging technique that tracks individual bacterial cells inside infected tissue. Using fluorescent markers that highlight gene activity, the team observed where C. diff cells were located and which cells activated toxin production during infection.

The analysis revealed that C. diff bacteria can spread throughout the gut and reside closer to the intestinal lining than previously thought. Surprisingly, only a small subset of bacterial cells produced toxins at any given time, suggesting that disease severity may be driven by specific subpopulations rather than overall bacterial numbers. The study, published in Nature Communications and PLOS Biology, also identified unusual filament-like shapes formed by highly toxin-producing strains during early infection stages, indicating that these cells may respond differently to environmental stress.

Researchers also examined how C. diff spores transition from a dormant state into active bacteria. Unlike most spore-forming bacteria, C. diff responds to bile acids and other digestive signals to trigger germination. The team identified two proteins—CspC and CspA—that work together as a signaling hub controlling this activation process. Structural analysis showed that this protein complex regulates how sensitive spores are to environmental signals that trigger growth.

These findings provide a clearer understanding of how C. diff infections develop, spread, and reactivate. By identifying the molecular mechanisms that control toxin production and spore germination, researchers hope to develop targeted treatments that block infection without disrupting beneficial gut bacteria. Future research will continue exploring unique biological processes in C. diff that could reveal new drug targets and help clinicians better predict which patients are at risk of severe or recurrent infection.

“The hope is the aspects that make C. diff unique—how it spreads, reproduces, and damages tissue—will allow researchers to design ways to target it much more specifically, while keeping the rest of the gut microbiome healthy and intact,” said associate professor Aimee Shen.

Related Links:
Tufts University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A simple daily blood test could help critically ill sepsis patients stop antibiotics sooner, reducing overuse and potentially helping combat antibiotic resistance (Image Credit: Adobe Stock)

Daily Blood Biomarker Testing May Help Guide Earlier Antibiotic Stopping in Sepsis

Sepsis is a life-threatening condition caused by the body’s overwhelming response to infection and accounts for thousands of deaths each year. In intensive care, concern about stopping treatment too early... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.